ISSN 0976 - 8157

Indexing & Abstracting: DOAJ, Index Copernicus, Chemical Abstract Services (CAS), EBSCO Publishing, Ulrich's Serial database, NewJour, GFMER, Science Central, Libraries Directory, IRNEM, Biblioteca, Open J-gate...........
Home Archive Volume 08,Issue 03,Year 2017
Volume 08,Issue 03,Year 2017

DocumentsDate added

Order by : Name | Date | Hits [ Ascendant ]

Original article

Zainab Mazin Taha Al-Kattan1, Wahda Basheer Al-Youzbaki2*,Yousif Bahaaddin Ahmed3

1Pharmacist, Nineveh Health Directorate, Ministry of Health, Mosul, Iraq
2Proffesor, Department of Pharmacology, College of Medicine, University of Mosul, Iraq
3Lecturer, Department of Internal Medicine, College of Medicine, Hawler Medical University, Iraq


Objective: To evaluate the effect of sitagliptin in combination with metformin and glibenclamide (triple therapy group) on glycemic control (fasting serum glucose (FSG) and glycated hemoglobin (HbA1c)) and homeostatic model assessment: insulin resistance (HOMA-IR)), in patients with type 2 diabetes mellitus (T2DM).
Methodology: This is a case control study conducted in Layla-Qassim Center for Diabetic Treatment in Erbil City, Iraq, from the 31th October 2015 to the 20th April 2016. One hundred sixty-five subjects were enrolled in this study. These participants were divided into four groups: apparently healthy group set as control (n=40), Dual therapy group T2DM (on metformin and glibenclamide treatment) (n=45), Triple therapy group T2DM (on sitagliptin, metformin and glibenclamide treatment) (n=42) and T2DM on diet group (n=38). From each subject the taken fasting blood sample was used for estimating the studied parameters using commercially available kits and by fully automated immunoassay and chemistry analyzers.
Results: This study showed a highly significant reduction in FSG (p= 0.0001) and HbA1c (p = 0.0001) in diabetic on triple therapy group when compared with diabetic on dual therapy group and on diet group. While a significant reduction in FSG (p= 0.03) but a non significant differences in HbA1c in T2DM patients on dual therapy group when compared with T2DM patients on diet group. This study found a significant reduction in HOMA-IR (p= 0.001), (p = 0.03) in diabetic on triple therapy group as compared with diabetic on diet and on dual therapy group respectively.
Conclusion: Combination of sitagliptin with metformin and glibenclamide (triple therapy) for more than three months in patients with T2DM, is associated with improvement in glycemic control and reduction in insulin resistance.

Keywords:  sitagliptin, diabetes mellitus, insulin resistance.

Address reprint to:Prof. Dr. Wahda Basheer Al-Youzbaki, PhD Pharmacology
Department of Pharmacology, College of Medicine, University of Mosul, Iraq

Published under Creative Commons Attribution (CC BY) license

Original article

Safa Hassan Omer1, Munish Kumar2, Mohammed Al-Gathradhi3, Sivakumar Vijayaraghavalu4*

1Department of Clinical Biochemistry, College of Medicine, King Khalid University (KKU), Abha, Kingdom of Saudi Arabia (KSA)
2 Department of Biochemistry, Allahabad University,  Allahabad, Uttar Pradesh, India
3Aseer Central Hospital, Ministry of Health, Abha, KSA
4Department of Pharmaceutical Chemistry, College of Pharmacy, KKU, Abha, KSA


Self-monitoring of blood glucose (SMBG) is a useful tool for effective diabetes management. However, its efficacy on glycemic control is controversial for type 2 diabetes mellitus (T2DM) patients. Hence, to resolve this discrepancy and to design an appropriate disease management plan for females with T2DM, this two year cross sectional retrospective and prospective study was carried out. For the study purpose 314 diabetics (age: 40-50; obesity grade I) with glycated hemoglobin (HbA1c) levels in the range of 9%-10% were divided equally into SMBG- and non-SMBG-group. Patients in the SMBG group were advised to monitor their blood glucose levels daily using a small lancet device, whereas no such instructions were given to non-SMBG group. Apart from this rest of the instructions and therapeutic regimen followed remained the same for both groups. Patients were recommended to follow healthy diet and perform walking as an exercise regularly for 30-70 min/1-3 mile/2,400 – 6,400 steps daily. To avoid the influence of different anti-diabetic drugs on the glycemic control, all patients were maintained on extended release tablets of metformin 1000 mg twice daily during the study period. Results of our study showed no significant influence of SMBG on glycemic control in T2DM females. Percent of patients consuming healthy diet and performing exercise was also comparable between the SMBG and non-SMBG groups. Thus awareness programs needs to be designed to improve the patient compliance and understanding of the disease. As well to modify the life style for better therapeutic outcome.

Keywords: SMBG, Metformin, Type 2 Diabetes Mellitus, Diet and Exercise, Women.

Address reprint to: Sivakumar Vijayaraghavalu, Ph.D.
Assistant Professor, Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia, P.O.Box:1882, Postal code:6144.

Published under Creative Commons Attribution (CC BY) license


Editorial Board

Who's Online

We have 40 guests online

Statistics Counter

joomla visitor


Do you think pharmaceutical companies should spend more on educating physicians about their products?

Social Widgets